Epilepsy, Focal-Onset Seizure
Conditions
Keywords
focal onset,lacosamide,CEA,Real-world,first add on
Brief summary
The purpose of this trial is to evaluate the efficacy, safety, and pharmaco-economics of Lacosamide Tablet as first add-on therapy for uncontrolled focal onset epilepsy ,invetigating effects of lacosamide Tablet on cognitive function of children and anxiety and depression of adults with focal onset seizures In real-world clinical setting
Detailed description
In many real world, lacosamide as the first add-on therapy can significantly improve the seizure freedom rate. Moreover, many pharmacoeconomic studies in Sweden and the United States have confirmed that lacosamide is a more cost-effective option.This is a real-world study to evaluate the efficacy, safety and cost-effectiveness of Generic lacoxamide tablets in the treatment of patients with focal epilepsy. During the trial, patients with focal epilepsy were treated with lacosamide for the first time after the failure of the original antiepileptic drug. At the same time, the cost-effectiveness of Generic lacosamide was evaluated from the perspective of economics, in order to provide the basis for the clinical choice for Chinese epilepsy patients.
Interventions
DRUGlacosamide
lacosamide as first add on therapy
Sponsors
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
4 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Before the start of the trial, to obtain the informed consent approved by the ethics committee voluntarily signed by each subject. For underage subjects, the informed consent jointly signed by the subjects themselves (≥10 years ) and their parents or legal guardian (in which the underage needs the signature with their parents or legal guardian, and the underage is defined as the subject under 18 years of age) ; * Male and female, between the ages of 4 and 75 years; * Diagnostic criteria of focal onset seizures (with or without focal to bilateral tonic clonic seizures) was based on the 2017 Classification of Epileptic Seizures from the International League Against Epilepsy (ILAE); * In the 4 weeks before enrollment and during the baseline period, patients have been on only one stable dosage of antiepileptic drug and suitable for lacosamide add-on therapy according to their investigators criteria; * During the 8-week retrospective baseline period, patients must have had at least 4 focal onset seizures per 28 days on average.
Exclusion criteria
* Patients had received previous lacosamide treatment; * Female patients are pregnant, breast-feeding, and will not use contraception during the trial; * Patients had known allergies to lacosamide or any ingredients of the drug, or with allergic constitution; * Patients have a history of status epilepticus in the last 12 months; * History of chronic alcohol or drug abuse; 6.history of suicide attempt or suicidal ideation in the past 6 months; * Current use of Antidepressants, anxiolytics or antipsychotics; * Patients suffer from progressive diseases that affect the patient's brain and its function; * Sychogenic nonepileptic seizures; * Patients suffer from serious lung and blood system diseases, malignant tumor, lower immune function and psychosis; * Patients wil receive ketogenic diet therapy, or Four weeks before entering the screening period, patients used other drugs that may affect the absorption, distribution, metabolism and excretion of lacosamide, such as antipsychotics, monoamine oxidase inhibitors, barbiturates (except for combined use as anticonvulsant therapy), narcotic analgesics. * Patients Had epilepsy brain surgery, or will undergo epilepsy surgery in the next four months. * Investigators considered Patients as unsuitable for this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ≥50responder rate | up to 26 weeks | percentage of subjects with a 50 % or greater reduction in seizure frequency per 4 weeks from retrospective baseline to maintenance |
| The change in seizure frequency per 4 week from retrospective baseline to the maintenance period | up to 26 weeks | The seizure frequency is standardized to a 4 week duration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Retention rate | up to 26 weeks | the percentage of patients continuing lacosamide at the end of a specified period |
| Evaluation for anxiety status | up to 24 weeks | using by seven-item Generalized Anxiety Disorder scale (GAD-7) |
| Evaluation for depression status | up to 24 weeks | using by Neurological Disorders Depression Inventory for Epilepsy(NDDI-E) |
| Cognitive function | up to 26 weeks | Cognitive function in elderly children aged greater than or equal to 6 years is assessed by Wechsler Intelligence Scale for Children-Revised (WISC-RC) ; |
| Seizure freedom rate | up to 26 weeks | percentage of subjects who achieved seizure-free during maintenance period |
Other
| Measure | Time frame | Description |
|---|---|---|
| the Cost of epilepsy treatment | up to 26 weeks | To calculate the direct medical costs, including personal expenses and medical insurance reimbursement expenses, mainly include examination expenses, disposal expenses, medicine expenses, hospitalization expenses and other expenses |
| Cost-Effectiveness Analysis(CEA） | up to 26 weeks | CEA=cost/efficacy(C/E) |
Countries
China
Contacts
Primary ContactRuipeng Zhang, MA
Outcome results
None listed